Systemic Lupus Erythematosus (SLE)

Rheumatology / Autoimmune

Overview

Definition

A chronic, relapsing, complex autoimmune disease characterized by the production of autoantibodies leading to widespread immune complex deposition and tissue damage.

Epidemiology

Highly disproportionate impact on women of childbearing age (9:1 female-to-male ratio). More common and severe in African American and Hispanic populations.

Etiology & Risk Factors

  • Multifactorial: Genetic predisposition, environmental triggers (UV light/sun exposure), and hormonal factors (estrogen).
  • Defective clearance of apoptotic cells leads to the production of anti-nuclear antibodies.

Clinical Symptoms

  • Constitutional: Fatigue, fever, weight loss
  • Dermatologic: Malar 'butterfly' rash (spares nasolabial folds), Discoid rash, Photosensitivity, Oral/Nasal ulcers
  • Musculoskeletal: Non-erosive polyarthritis (migratory, symmetrical)
  • Renal: Lupus Nephritis (causes hypertension, edema, hematuria, proteinuria)
  • Hematologic: Anemia, leukopenia, thrombocytopenia

Clinical Approach

Diagnosis

  • Screening: Anti-Nuclear Antibody (ANA) - Highly sensitive, almost 100% positive in SLE. If negative, SLE is extremely unlikely.
  • Confirmation: Anti-dsDNA (highly specific, correlates with disease activity/lupus nephritis) and Anti-Smith (highly specific, does not correlate with activity)
  • Complement Levels: Decreased C3 and C4 during active flares (due to consumption by immune complexes)

Management

  • Hydroxychloroquine: The cornerstone of therapy. Recommended for ALL patients to reduce flares and mortality (Requires annual eye exams for retinal toxicity)
  • Mild flares (joint/skin): NSAIDs and low-dose Corticosteroids
  • Severe organ-threatening disease (Lupus Nephritis, CNS lupus): High-dose Corticosteroids, Cyclophosphamide, or Mycophenolate Mofetil

Complications

  • Lupus Nephritis (a leading cause of morbidity and mortality)
  • Accelerated atherosclerosis and premature cardiovascular disease
  • Libman-Sacks Endocarditis (non-bacterial verrucous vegetations on heart valves)
  • Increased risk of infection (due to disease and immunosuppressants)